SUPN

$30.4827.29%-11.44

Supernus Pharmaceuticals Inc (SUPN)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$41.92

Aprire:

$28.35

Volume 24 ore:

980,487

Volume relativo:

0.72

Capitalizzazione di mercato:

$1.78B

Reddito:

$776.83M

Utile/perdita netta:

-$29.02M

Rapporto P/E:

EPS:

-$0.512

Flusso di cassa netto:

$82.25M

1W Prestazione:

-25.59%

1M Prestazione:

-28.08%

6M Prestazione:

-36.30%

1Y Prestazione:

-45.28%

Intervallo 1D:

$28.35$31.20

Intervallo di 1 settimana:

$39.53$44.31

Portata 52W:

$28.35$59.68

Profilo aziendale di Supernus Pharmaceuticals Inc (SUPN)

Nome

Supernus Pharmaceuticals Inc

Settore

Healthcare

Industria

Drug Manufacturers - Specialty & Generic

Telefono

301-838-2500

Indirizzo

9715 KEY WEST AVENUE, ROCKVILLE, MD, USA

Dipendente

778

@Supernus_Pharma

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di SUPN su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Supernus Pharmaceuticals Inc Azioni (SUPN) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2025-10-09	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-07-30	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2025-02-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-01-06	Iniziato	Cantor Fitzgerald	Overweight
2024-09-11	Downgrade	Piper Sandler	Overweight → Neutral
2023-01-03	Resumed	Jefferies	Buy
2021-12-01	Resumed	Jefferies	Buy
2021-04-13	Aggiornamento	Jefferies	Hold → Buy
2020-06-16	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-06-15	Resumed	Jefferies	Hold
2019-11-08	Downgrade	Berenberg	Buy → Hold
2019-11-07	Downgrade	Stifel	Buy → Hold
2019-11-06	Downgrade	Jefferies	Buy → Hold
2018-11-12	Reiterato	B. Riley FBR	Buy
2018-01-18	Reiterato	B. Riley FBR, Inc.	Buy
2017-12-28	Reiterato	B. Riley FBR, Inc.	Buy
2017-12-04	Aggiornamento	Janney	Neutral → Buy
2017-11-08	Aggiornamento	Stifel	Hold → Buy
2017-10-19	Iniziato	FBR & Co.	Buy
2017-09-19	Downgrade	Stifel	Buy → Hold
2017-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
2017-07-14	Iniziato	Janney	Neutral
2017-06-01	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-07-18	Downgrade	Northland Capital	Outperform → Market Perform
2016-07-18	Downgrade	Piper Jaffray	Overweight → Neutral
2016-02-08	Aggiornamento	Jefferies	Hold → Buy
2015-11-05	Reiterato	Northland Capital	Outperform
2015-10-28	Iniziato	Northland Capital	Outperform

Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31
Revenue USD (M)	718.95	661.82	667.24	579.78	520.40
Cost of revenue USD (M)	74.56	77.91	-	-	52.46
Gross profit USD (M)	-	-	-	-	467.94
Research and development USD (M)	106.24	108.80	74.55	90.47	75.96
Operating expenses USD (M)	781.24	580.15	621.11	493.75	294.24
Operating income USD (M)	-62.28	81.67	46.12	86.03	173.70
Income before tax USD (M)	-49.03	97.87	60.74	73.18	168.65
Income tax expense USD (M)	-10.48	24.01	0.03	19.75	41.70
Net income USD (M)	-38.55	73.87	60.71	53.42	126.95
Basic EPS USD/shares	-0.68	1.34	1.13	1.01	2.41
Diluted EPS USD/shares	-0.68	1.32	1.04	0.98	2.36
Basic weighted shares shares (M)	56.45	55.10	53.67	53.10	52.62
Diluted weighted shares shares (M)	56.45	55.96	61.68	54.36	53.69
Selling, general and administrative USD (M)	485.56	321.58	377.22	304.76	200.68

Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading

Rubin JonathanAug 12 '26
SVP, Chief Medical Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
750
Valore ($)
0
#Azioni Totale
14,342
DEC TIMOTHY CAug 12 '26
Senior Vice-President & CFO
Transazione
Option Exercise
Costo
$0.00
#Azioni
1,250
Valore ($)
0
#Azioni Totale
9,733
Khattar Jack A.Aug 12 '26
President, CEO
Transazione
Option Exercise
Costo
$0.00
#Azioni
29,849
Valore ($)
0
#Azioni Totale
1,270,993
Mottola FrankAug 12 '26
SVP, Chief Tech. Ops. Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
1,650
Valore ($)
0
#Azioni Totale
20,341
Bhatt Padmanabh P.Aug 12 '26
Sr. VP of IP, CSO
Transazione
Option Exercise
Costo
$0.00
#Azioni
2,500
Valore ($)
0
#Azioni Totale
19,795
Bhatt Padmanabh P.Mar 18 '26
Sr. VP of IP, CSO
Transazione
Option Exercise
Costo
$39.40
#Azioni
7,250
Valore ($)
285,650
#Azioni Totale
24,294
Bhatt Padmanabh P.Mar 18 '26
Sr. VP of IP, CSO
Transazione
Sale
Costo
$49.60
#Azioni
7,250
Valore ($)
359,621
#Azioni Totale
17,044
Bhatt Padmanabh P.Mar 17 '26
Sr. VP of IP, CSO
Transazione
Option Exercise
Costo
$38.51
#Azioni
50,000
Valore ($)
1,925,537
#Azioni Totale
67,044
PADMANABH P BHATTMar 17 '26
Officer
Transazione
Proposed Sale
Costo
$50.21
#Azioni
57,250
Valore ($)
2,874,522
#Azioni Totale
0
Bhatt Padmanabh P.Mar 17 '26
Sr. VP of IP, CSO
Transazione
Sale
Costo
$50.30
#Azioni
50,000
Valore ($)
2,514,886
#Azioni Totale
17,044

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Rubin Jonathan	SVP, Chief Medical Officer	Aug 12 '26	Option Exercise	$0.00	750	0	14,342
DEC TIMOTHY C	Senior Vice-President & CFO	Aug 12 '26	Option Exercise	$0.00	1,250	0	9,733
Khattar Jack A.	President, CEO	Aug 12 '26	Option Exercise	$0.00	29,849	0	1,270,993
Mottola Frank	SVP, Chief Tech. Ops. Officer	Aug 12 '26	Option Exercise	$0.00	1,650	0	20,341
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Aug 12 '26	Option Exercise	$0.00	2,500	0	19,795
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Option Exercise	$39.40	7,250	285,650	24,294
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Sale	$49.60	7,250	359,621	17,044
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Option Exercise	$38.51	50,000	1,925,537	67,044
PADMANABH P BHATT	Officer	Mar 17 '26	Proposed Sale	$50.21	57,250	2,874,522	0
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Sale	$50.30	50,000	2,514,886	17,044

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

Nov 02, 2026

Why Indivior Pharmaceuticals Stock Topped the Market Today - The Motley Fool

Nov 02, 2026

Oct 31, 2026

SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger - Yahoo Finance

Oct 31, 2026

Oct 30, 2026